Pathomechanisms in celiac disease

被引:47
作者
Dieterich, W [1 ]
Esslinger, B [1 ]
Schuppan, D [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Med 1, DE-91054 Erlangen, Germany
基金
美国国家卫生研究院;
关键词
autoantibody; autoimmunity; celiac disease; gliadin; gluten; HLA-DQ2/DQ8; transglutaminase;
D O I
10.1159/000073710
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Celiac disease is a complex autoimmune disease which is characterized by a strong genetic association (HLA-DQ2 or -DQ8), gluten as nutritional etiological factor, and the enzyme tissue transglutaminase as endomysial autoantigen. Patients develop highly predictive IgA autoantibodies to tTG. Certain gluten peptides are presented by the disease-associated HLA-DQ2/DQ8 molecules leading to stimulation of gluten-specific T cells. This immune response which is driven in the lamina propria causes the mucosal transformation characteristic for celiac disease. Increased intestinal expression of tTG in patients with CD appears to play an important role in the pathogenesis of CD. Thus, modification of gluten peptides by tTG, especially deamidation of certain glutamine residues, can enhance their binding to HLA-DQ2 or -DQ8 and potentiate T cell stimulation. Furthermore, tTG-catalyzed cross-linking and consequent haptenization of gluten with extracellular matrix proteins allows for storage and extended availability of gluten in the mucosa. New therapeutic approaches aim at proteolytic destruction of immunodominant gliadin peptides that are resistant to intestinal enzymes by bacterial prolyl endopeptidases, the inhibition of tTG activity with highly specific enzyme inhibitors or at HLA-DQ2/DQ8 blocking peptide analogues. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:98 / 108
页数:11
相关论文
共 105 条
[11]  
Brusco G, 1999, CLIN EXP IMMUNOL, V118, P371
[12]  
Brusco G, 1998, ITAL J GASTROENTEROL, V30, P496
[13]   Antibodies against human tissue transglutaminase and endomysium in diagnosing and monitoring coeliac disease [J].
Bürgin-Wolff, A ;
Dahlbom, I ;
Hadziselimovic, F ;
Petersson, CJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (06) :685-691
[14]   Onset of coeliac disease during treatment with interferon for chronic hepatitis C [J].
Cammarota, G ;
Cuoco, L ;
Cianci, R ;
Pandolfi, F ;
Gasbarrini, G .
LANCET, 2000, 356 (9240) :1494-1495
[15]   CLINICAL-TESTING OF GLIADIN FRACTIONS IN CELIAC PATIENTS [J].
CICLITIRA, PJ ;
EVANS, DJ ;
FAGG, NLK ;
LENNOX, ES ;
DOWLING, RH .
CLINICAL SCIENCE, 1984, 66 (03) :357-364
[16]   Insulin-dependent diabetes mellitus and coeliac disease [J].
Cronin, CC ;
Shanahan, F .
LANCET, 1997, 349 (9058) :1096-1097
[17]   Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease [J].
Daum, S ;
Bauer, U ;
Foss, HD ;
Schuppan, D ;
Stein, H ;
Riecken, EO ;
Ullrich, R .
GUT, 1999, 44 (01) :17-25
[18]   INVITRO (ORGAN-CULTURE) STUDIES OF THE TOXICITY OF SPECIFIC A-GLIADIN PEPTIDES IN CELIAC-DISEASE [J].
DERITIS, G ;
AURICCHIO, S ;
JONES, HW ;
LEW, EJL ;
BERNARDIN, JE ;
KASARDA, DD .
GASTROENTEROLOGY, 1988, 94 (01) :41-49
[19]   Autoantibodies to tissue transglutaminase as predictors of celiac disease [J].
Dieterich, W ;
Laag, E ;
Schöpper, H ;
Volta, U ;
Ferguson, A ;
Gillett, H ;
Riecken, EO ;
Schuppan, D .
GASTROENTEROLOGY, 1998, 115 (06) :1317-1321
[20]   Identification of tissue transglutaminase as the autoantigen of celiac disease [J].
Dieterich, W ;
Ehnis, T ;
Bauer, M ;
Donner, P ;
Volta, U ;
Riecken, EO ;
Schuppan, D .
NATURE MEDICINE, 1997, 3 (07) :797-801